Short interest for Magic Empire Glb gives investors a sense of the degree to which investors are betting on the decline of Magic Empire Glb's stock. Short interest data is updated every two weeks.

Magic Empire Glb Stock (NASDAQ:MEGL), Short Interest Report

Magic Empire Global

Magic Empire Global Ltd is a financial services provider in Hong Kong which principally engaged in the provision of corporate finance advisory services and underwriting services.

News

Penny Stocks

Small Cap

Pre-Market Outlook

Markets

Movers

Trading Ideas

ATRA

BCEL

BETS

BIOR

CAMP

CANO

CCTG

CHEA

CVKD

DCFC

FDMT

GRDI

MEGL

NEXI

NSTG

TWOU

WORX

Shares of 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) rose sharply in today’s pre-market trading.

4DMT presented interim data from randomized Phase 2 PRISM clinical trial of intravitreal 4D-150 demonstrating favorable tolerability &amp; clinical activity in wet AMD.

Why 4D Molecular Therapeutics Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket

Intraday Update

ANIP

BAOS

BLCM

BTBT

BTOG

CLSK

CRKN

CTLT

EZFL

FRBK

FUBO

GDOT

GLMD

GTEC

HLTH

IDEX

IMPP

IMRN

INOD

IONM

LYEL

MARA

MDJH

MINM

NBTX

NSSC

OKYO

OPEN

RIOT

SVFD

TNYA

TRUP

TRVN

USGO

VCIG

ZAPP

Gainers


	Trevena, Inc. (NASDAQ: TRVN) shares surged 170% to $1.74 after the company announced the approval of OLINVYK in China.


Why Tredegar Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Monday&#39;s Mid-Day Session

HCDI

HSCS

SVRE

Gainers


	Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM) gained 105.2% to $0.8001 in pre-market trading. Bellicum Pharmaceuticals 13D filing showed Baker Bros. Advisors reported a 19.99% active stake in the company.


Why Bellicum Pharmaceuticals Shares Are Trading Higher By 105%; Here Are 20 Stocks Moving Premarket

Magic Empire Global Limited - Ordinary Shares

Magic Empire Global Ltd

The crypto world was rocked when Changpeng Zhao, the enigmatic founder and CEO of Binance (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/bnb/usd">BNB</a>), the world&#8217;s largest cryptocurrency exchange, was sentenced to four months in prison for his role in failing to establish an effective anti-money laundering (AML) <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38532677/former-binance-ceo-changpeng-zhao-sentenced-to-four-months-in-prison">program at the cryptocurrency exchange.</a>
While Zhao&#8217;s legal troubles were brewing, his successor, Richard Teng, had already quietly assumed the reins as CEO, tasked with steering the exchange through this turbulent period.
Who is Teng and what does his leadership mean for the future of Binance?
Richard Teng: A Regulator Steps In
Prior to taking the helm at Binance, Teng held a crucial role as the Chief Compliance Officer, leveraging his experience as a former regulator at Singapore&#8217;s central bank. 
This background positions him strategically to navigate the increasingly complex regulatory landscape surrounding cryptocurrency exchanges.
Teng&#8217;s leadership has been marked by a clear focus on compliance. 
He has publicly acknowledged the need for significant changes within Binance, stating that the exchange&#8217;s previous approach to regulation was &#8220;inadequate.&#8221; 
This shift is evident in several key initiatives, including:
<ul>
<li>Establishing a Global Headquarters: Previously operating with a decentralized structure, Binance is now actively seeking a physical headquarters, a move that signals a willingness to cooperate with regulatory bodies.</li>
<li>Re-entering Regulated Markets: Binance has made efforts to re-enter markets like India and Thailand, demonstrating a commitment to adhering to local regulations.</li>
<li>Increased Transparency: Teng has emphasized the importance of transparency and user protection, initiatives that could potentially rebuild trust with regulators and users alike.</li>
</ul>
Before joining Binance, Teng was recognized for his innovative regulatory approaches at Abu Dhabi Global Market and had pivotal roles at the Monetary Authority of Singapore and the Singapore Exchange​​. 
His expertise is seen as pivotal in navigating Binance through its complex regulatory challenges, especially after the company agreed to a landmark $4.3 billion settlement with U.S. authorities over accusations of violating sanctions and money-transmitting laws​.
Under Teng&#8217;s leadership, Binance is not just focusing on rectifying past issues but is also pushing forward with new initiatives. 
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/"><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/27091545/Benzinga-conference.gif" alt="Benzinga future of digital assets conference" class="wp-image-267246" /></a></figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/05/38547115/ex-binance-ceo-changpeng-zhao-sees-crypto-industry-entering-new-phase">Ex-Binance CEO Changpeng Zhao Sees Crypto Industry Entering &#8216;New Phase&#8217;</a>
The company has ramped up its compliance measures, strategically hiring key talents from regulatory bodies and major financial institutions. 
This focus on compliance is part of Teng&#8217;s broader strategy to foster trust and ensure Binance&#8217;s growth in the highly scrutinized cryptocurrency market​​.
Moreover, Teng is setting his sights on broadening Binance's operations, with significant expansions in the Middle East and Europe. 
The United Arab Emirates and France have been chosen as regional headquarters, reflecting Teng&#8217;s familiarity with the MENA region and the strategic importance of the European market under the new Markets in Crypto-Assets (MiCA) regulation​.
Challenges And Uncertainties Remain
Despite these efforts, Binance still faces significant challenges. 
The SEC&#8217;s lawsuit against Binance.US, Zhao, and Teng himself, alleging unregistered exchange operations and commingling of user funds, looms large. 
Additionally, regulatory scrutiny in various regions continues to cast a shadow over the exchange&#8217;s global operations.
The Road Ahead: A New Era For Binance?
While Zhao&#8217;s return after his sentence is expected, the long-term impact of his imprisonment and the changing regulatory landscape remain to be seen. 
Richard Teng&#8217;s leadership presents an opportunity for Binance to embrace a more compliant and transparent approach, potentially paving the way for a new era of stability and growth.
However, navigating the intricate web of global regulations and regaining the trust of both regulators and users will be a monumental task. 
The success of Teng&#8217;s leadership will hinge on his ability to effectively address these challenges and steer Binance towards a more sustainable future.
Looking Towards The Future Of Digital Assets
Events like Benzinga&#8217;s <a href="https://www.benzinga.com/events/digital-assets/agenda/">Future of Digital Assets</a> on Nov. 19 will be crucial platforms for industry leaders and experts to dissect the evolving regulatory landscape and its impact on major players like Binance. 
Read Next: <a href="https://www.benzinga.com/markets/cryptocurrency/24/05/38546670/us-stablecoin-regulation-talks-stall-but-progress-is-near">US Stablecoin Regulation Talks Stall, But Progress Is Near</a>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BNB

Who Is Binance's New CEO Richard Teng And Can He Fill CZ's Shoes?

RBC Capital analyst Ken Herbert maintains Leidos Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LDOS#NYSE">LDOS</a>) with a Sector Perform and raises the price target from $120 to $140.

Price Target

Analyst Ratings

LDOS

RBC Capital Maintains Sector Perform on Leidos Holdings, Raises Price Target to $140

Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>), Taiwan Semiconductor Manufacturing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>), and London Stock Exchange Group saw increased investments from Third Point LLC due to their AI-driven opportunities. 
Daniel Loeb, founder and CEO, highlighted its significant distribution and technological edge over competitors. In his investor letter, Loeb praised Alphabet&#8217;s ability to leverage AI to improve and monetize its product suite.&nbsp;
Additionally, Third Point increased its stakes in Taiwan Semiconductor Manufacturing Co. and London Stock Exchange Group,&nbsp;which&nbsp;were attracted&nbsp;by AI-driven opportunities, Bloomberg&nbsp;<a target="_blank" href="https://www.bloomberg.com/news/articles/2024-04-30/loeb-s-third-point-says-ai-makes-up-almost-50-of-stock-exposure?srnd=technology-vp&amp;sref=TBDibEcD" rel="noreferrer noopener">reports</a>.
Despite underperforming the broader market, with a 7.8% gain compared to the S&amp;P 500&#8217;s nearly 11% return, Third Point&#8217;s flagship fund reported solid results for the first quarter, buoyed by strong performances from major tech stocks such as&nbsp;Meta Platforms Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) and&nbsp;Amazon.com Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>).&nbsp;
Loeb noted that the technological shift favors established companies investing heavily to dominate the AI landscape.&nbsp;
This trend&nbsp;was mirrored&nbsp;by other hedge funds&nbsp;like&nbsp;David Einhorn&#8217;s Greenlight Capital, which also fell short of the S&amp;P 500 with a 4.9% return.
Last week, Alphabet&nbsp;<a target="_blank" href="https://www.benzinga.com/news/earnings/24/04/38445001/alphabet-q1-earnings-revenue-beat-eps-beat-70b-buyback-first-ever-dividend-ai-leadership-and-more" rel="noreferrer noopener">reported first-quarter</a>&nbsp;revenue growth of 15% year-over-year to $80.539 billion, beating the analyst&nbsp;consensus estimate&nbsp;of $78.594 billion. The company reported EPS of $1.89, beating analyst consensus estimate of $1.51. Google Cloud revenue totaled $9.574 billion.
The board authorized an additional share repurchase program of up to $70 billion and announced its first-ever quarterly dividend per share of $0.20.
In April, TSMC reported&nbsp;<a target="_blank" href="https://www.benzinga.com/news/earnings/24/04/38320056/whats-going-on-with-apple-supplier-taiwan-semi-stock-on-thursday" rel="noreferrer noopener">first-quarter revenue</a>&nbsp;growth of&nbsp;16.5% to $18.87 billion, surpassing the Street consensus estimate of $18.40 billion. Advanced technologies accounted for 65% of TSMC&#8217;s total revenue.&nbsp;
<a target="_blank" href="https://www.benzinga.com/news/24/04/38498886/microsoft-meta-and-alphabet-ramp-up-ai-investments-spend-over-32b-in-q1" rel="noreferrer noopener">Recent reports indicated</a>&nbsp;that tech giants&nbsp;Microsoft Corp&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), Meta, and Alphabet invested over $32 billion in AI infrastructure in the first quarter alone.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Illustration created using artificial intelligence via DALL-E

Tech

Media

AMZN

GOOG

GOOGL

MSFT

Third Point's AI Focus Pays Off As Investments in Alphabet and TSMC Propel Q1 Growth

RBC Capital analyst Ashish Sabadra maintains Ecolab (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ECL#NYSE">ECL</a>) with a Outperform and raises the price target from $238 to $260.

RBC Capital Maintains Outperform on Ecolab, Raises Price Target to $260

Shares of Advanced Micro Devices, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) fell sharply during Wednesday's session as the company reported first-quarter results and issued revenue <a href="https://www.benzinga.com/news/earnings/24/04/38534910/amd-investors-pull-back-after-modest-q1-beat-ceo-touts-ai-chip-ramp-up">guidance for the second quarter</a>.
AMD guided to second-quarter revenue of $5.7 billion plus or minus $300 million and a non-GAAP gross margin of about 53% against Street estimates of $5.7 billion in second-quarter revenue. Street expectations for fiscal year 2024 are for earnings of $3.40 per share and revenue of $24.13 billion, respectively, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Advanced Micro Devices shares dipped 6.9% to $147.44 on Wednesday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>CytomX Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTMX#NASDAQ">CTMX</a>) shares jumped 97.5% to $3.2199. CytomX Therapeutics will report first quarter 2024 results and issue an initial CX-904 Phase 1a clinical data update on May 8.</li>
<li>IM Cannabis Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMCC#NASDAQ">IMCC</a>) gained 41.3% to $1.2150 after jumping around 54% on Tuesday.</li>
<li>Akanda Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKAN#NASDAQ">AKAN</a>) gained 39.5% to $0.1295. Shares of cannabis-related stocks traded higher following reports suggesting the DEA plans to reclassify cannabis as a less dangerous drug.</li>
<li>Getaround, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GETR#NYSE">GETR</a>) rose 35% to $0.2741 after the company announced it secured up to $50 million in additional financing.</li>
<li>Rocky Brands, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCKY#NASDAQ">RCKY</a>) gained 31.6% to $33.93 after the company reported better-than-expected quarterly financial results.</li>
<li>Palisade Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PALI#NASDAQ">PALI</a>) shares climbed 28% to $7.72 after the company announced completion of its analysis to determine the effects of bioactivated PALI-2108 on TNF-α production in a whole blood assay.</li>
<li>TransMedics Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>) shares rose 28% to $120.26 after the company raised its 2024 guidance.</li>
<li>Surmodics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRDX#NASDAQ">SRDX</a>) gained 27.2% to $32.69 following strong quarterly results.</li>
<li>DecisionPoint Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPSI#NASDAQ">DPSI</a>) rose 24.6% to $10.03 as the company agreed to go private in all-cash transaction.</li>
<li>CareDx, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) rose 23.4% to $9.59. CareDx is expected to report financial results for the first quarter 2024 after the closing bell on Thursday, May 9.</li>
<li>Powell Industries, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POWL#NASDAQ">POWL</a>) jumped 23.2% to $176.16 after the company reported better-than-expected second-quarter financial results.</li>
<li>TG Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGTX#NASDAQ">TGTX</a>) rose 21.7% to $16.64 following a first-quarter revenue beat and increased 2024 Briumvi US net product revenue outlook.</li>
<li>New York Community Bancorp, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NYCB#NYSE">NYCB</a>) climbed 20% to $3.1887 following quarterly results.</li>
<li>Bio-Techne Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECH#NASDAQ">TECH</a>) jumped 20.1% to $75.89 following upbeat quarterly results.</li>
<li>Inari Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NARI#NASDAQ">NARI</a>) shares gained 19.1% to $44.47 after the company reported better-than-expected first-quarter sales results and issued FY24 revenue guidance above estimates.</li>
<li>LendingClub Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LC#NYSE">LC</a>) gained 18% to $8.87.</li>
<li>A10 Networks, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATEN#NYSE">ATEN</a>) gained 17.7% to $15.38 following better-than-expected quarterly results.</li>
<li>Pinterest, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PINS#NYSE">PINS</a>) rose 17.5% to $39.29 following strong first-quarter earnings and upbeat second-quarter guidance.</li>
<li>Root, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROOT#NASDAQ">ROOT</a>) shares climbed 17.2% to $81.66 after the company reported better-than-expected first-quarter financial results.</li>
<li>LendingClub Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LC#NYSE">LC</a>) gained 17.2% to $8.82 following upbeat earnings.</li>
<li>UFP Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UFPT#NASDAQ">UFPT</a>) jumped 13.8% to $234.34 following upbeat earnings.</li>
<li>Conduent Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNDT#NASDAQ">CNDT</a>) rose 13.7% to $3.58 after the company reported better-than-expected first-quarter results and issued strong FY24 guidance.</li>
<li>Stagwell Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STGW#NASDAQ">STGW</a>) gained 13.1% to $6.73 following upbeat earnings.</li>
<li>The Chefs&#8217; Warehouse, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHEF#NASDAQ">CHEF</a>) climbed 11.5% to $36.89 following strong quarterly earnings.</li>
<li>Garmin Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRMN#NASDAQ">GRMN</a>) rose 11% to $160.40 after the company reported better-than-expected first-quarter financial results and affirmed FY24 adjusted EPS and sales guidance, which is above estimates.</li>
<li>Predictive Oncology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POAI#NASDAQ">POAI</a>) rose 9.9% to $1.5699 after the company announced a collaboration with FluGen for an intranasal flu vaccine.</li>
<li>Trinity Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRN#NYSE">TRN</a>) gained 9.4% to $28.48 following upbeat earnings.</li>
<li>Plutonian Acquisition Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTN#NASDAQ">PLTN</a>) gained 6.8% to $9.48.</li>
<li>Lion Group Holding Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGHL#NASDAQ">LGHL</a>) shares gained 6.5% to $0.5188 after the company reported a year-over-year increase in FY23 financial results.</li>
<li>Lemonade, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMND#NYSE">LMND</a>) shares gained 6% to $18.26 after the company reported better-than-expected first-quarter financial results and raised its FY24 revenue guidance above estimates.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Cemtrex, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CETX#NASDAQ">CETX</a>) shares fell 73.1% to $0.3054 after the company announced pricing of a $10 million upsized underwritten public offering.</li>
<li>Mobile-health Network Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDR#NASDAQ">MNDR</a>) dipped 61.8% to $9.41.</li>
<li>CVRx, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVRX#NASDAQ">CVRX</a>) fell 40.2% to $9.27 after the company reported worse-than-expected first-quarter financial results. JP Morgan analyst Robbie Marcus downgraded the stock from Overweight to Neutral and lowered the price target from $36 to $13.</li>
<li>Leggett &amp; Platt, Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEG#NYSE">LEG</a>) fell 29.1% to $12.81 after the company reported worse-than-expected first-quarter financial results. The company also reduced its dividend.</li>
<li>Concord Medical Services Holdings Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCM#NYSE">CCM</a>) dipped 28.8% to $0.6052.</li>
<li>XTI Aerospace, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XTIA#NASDAQ">XTIA</a>) fell 25.5% to $1.90</li>
<li>Canopy Growth Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) dipped 25% to $11.16.</li>
<li>Visionary Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GV#NASDAQ">GV</a>) declined 22.3% to $0.1883.</li>
<li>Astec Industries, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTE#NASDAQ">ASTE</a>) fell 21.1% to $32.99 following downbeat quarterly results.</li>
<li>CVS Health Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) dipped 19.4% to $54.55 following worse-than-expected first-quarter EPS and revenues.</li>
<li>Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) shares declined 15.9% to $721.99 following mixed third-quarter financial results.</li>
<li>Starbucks Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) fell 15.8% to $74.54 following weaker-than-expected second-quarter earnings.</li>
<li>Ryerson Holding Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RYI#NYSE">RYI</a>) declined 15.1% to $24.25 after posting a loss for the first quarter.</li>
<li>DigitalBridge Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBRG#NASDAQ">DBRG</a>) fell 14.4% to $14.08 after the company reported first-quarter financial results.</li>
<li>Hillenbrand, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HI#NYSE">HI</a>) dipped 14% to $41.04 after the company reported mixed second-quarter financial results and cut FY24 adjusted EPS guidance below estimates.</li>
<li>Skyworks Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWKS#NASDAQ">SWKS</a>) shares fell 13.7% to $92.01 after the company reported second-quarter financial results and issued third-quarter revenue guidance with the midpoint below estimates.</li>
<li>Sobr Safe Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOBR#NASDAQ">SOBR</a>) shares declined 12.2% to $0.2801.</li>
<li>SiteOne Landscape Supply, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SITE#NASDAQ">SITE</a>) fell 11.6% to $138.66 after the company reported mixed first-quarter financial results.</li>
<li>Norwegian Cruise Line Holdings Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NCLH#NYSE">NCLH</a>) fell 11% to $16.84 following a first-quarter revenue miss and soft FY24 guidance.</li>
<li>O-I Glass, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OI#NYSE">OI</a>) fell 10.5% to $13.38 after the company reported worse-than-expected first-quarter sales results and cut FY24 adjusted EPS guidance.</li>
<li>The Estée Lauder Companies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EL#NYSE">EL</a>) fell 9.7% to $132.39 after the company reported third-quarter financial results and issued FY24 adjusted EPS guidance below estimates.</li>
<li>Global Payments Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPN#NYSE">GPN</a>) fell 9% to $111.68 after the company reported first-quarter financial results and issued guidance.</li>
<li>Block, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQ#NYSE">SQ</a>) dipped 8.8% to $66.59. A report earlier today indicated federal prosecutors are examining the company&#8217;s financial transactions.</li>
<li>The Carlyle Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CG#NASDAQ">CG</a>) fell 8.2% to $41.10 after the company reported first-quarter financial results.</li>
<li>Polestar Automotive Holding UK PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNY#NASDAQ">PSNY</a>) shares declined 7.9% to $1.2801. Polestar delayed annual report due to accounting errors.</li>
<li>The Kraft Heinz Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KHC#NASDAQ">KHC</a>) fell 6.3% to $36.19 following mixed first-quarter results.</li>
<li>The Clorox Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) fell 6% to $139.09 after the company reported worse-than-expected third-quarter sales results.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/05/38550761/how-to-earn-500-a-month-from-intel-stock-following-q1-earnings-report">How To Earn $500 A Month From Intel Stock Following Q1 Earnings Report</a>

AKAN

ASTE

ATEN

CDNA

CETX

CHEF

CNDT

CTMX

CVRX

DBRG

DPSI

GETR

GRMN

IMCC

LGHL

LMND

MNDR

NARI

NCLH

NYCB

PALI

PINS

PLTN

POAI

POWL

PSNY

RCKY

ROOT

SBUX

SITE

SMCI

SOBR

SRDX

STGW

SWKS

TECH

TGTX

TMDX

UFPT

XTIA

Why AMD Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

RBC Capital analyst Dan Bergstrom maintains CommVault Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVLT#NASDAQ">CVLT</a>) with a Sector Perform and raises the price target from $97 to $112.

CVLT

RBC Capital Maintains Sector Perform on CommVault Systems, Raises Price Target to $112

In the latest quarter, 18 analysts provided ratings for Dollar Tree (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>), showcasing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">10</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Dollar Tree, revealing an average target of $156.5, a high estimate of $180.00, and a low estimate of $140.00. Experiencing a 1.29% decline, the current average is now lower than the previous average price target of $158.54. 
<img src="https://www.benzinga.com/files/images/story/2024/1714582874_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
A clear picture of Dollar Tree's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bradley Thomas</td>
<td>Keybanc</td>
<td>Announces</td>
<td>Overweight</td>
<td>$150.00</td>
<td>-</td>
</tr>
<tr>
<td>Greg Melich</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$142.00</td>
<td>$144.00</td>
</tr>
<tr>
<td>Matthew Boss</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$152.00</td>
<td>$144.00</td>
</tr>
<tr>
<td>Chuck Grom</td>
<td>Gordon Haskett</td>
<td>Lowers</td>
<td>Hold</td>
<td>$140.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Greg Melich</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$145.00</td>
<td>$144.00</td>
</tr>
<tr>
<td>Anthony Chukumba</td>
<td>Loop Capital</td>
<td>Lowers</td>
<td>Buy</td>
<td>$170.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>Michael Montani</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$144.00</td>
<td>$157.00</td>
</tr>
<tr>
<td>Kelly Bania</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$160.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Peter Keith</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$168.00</td>
<td>$171.00</td>
</tr>
<tr>
<td>Scot Ciccarelli</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$147.00</td>
<td>$149.00</td>
</tr>
<tr>
<td>Matthew Boss</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$144.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$160.00</td>
<td>-</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$160.00</td>
<td>-</td>
</tr>
<tr>
<td>Matthew Boss</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$165.00</td>
<td>$157.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$160.00</td>
<td>-</td>
</tr>
<tr>
<td>John Heinbockel</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$170.00</td>
<td>$155.00</td>
</tr>
<tr>
<td>Edward Kelly</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$180.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Chuck Grom</td>
<td>Gordon Haskett</td>
<td>Announces</td>
<td>Buy</td>
<td>$160.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Dollar Tree. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Dollar Tree compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Dollar Tree's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Dollar Tree's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/DLTR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Dollar Tree analyst ratings.</a>
<h2>All You Need to Know About Dollar Tree</h2>
Dollar Tree operates discount stores across the United States and Canada, with over 8,400 shops under its namesake banner and 8,350 under Family Dollar. About 47% of Dollar Tree's sales in fiscal 2023 were composed of consumables (including food, health and beauty, and cleaning products), around 45% from variety items (including toys and homewares), and over 5% from seasonal items. The Dollar Tree banner sells most of its merchandise at the $1.25 price point and positions its stores in well-populated suburban markets. Conversely, Family Dollar primarily sells consumable merchandise (80% of the banner's sales) at prices below $10. About two-thirds of Family Dollar's stores are located in urban and suburban markets, with the remaining one-third located in rural areas.
<h3>A Deep Dive into Dollar Tree's Financials</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Dollar Tree's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 11.91% as of 31 January, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Consumer Staples sector.
Net Margin: Dollar Tree's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -19.79%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Dollar Tree's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -20.96%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -7.43%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Dollar Tree's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.42.
<h2>How Are Analyst Ratings Determined?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

DLTR

Breaking Down Dollar Tree: 18 Analysts Share Their Views

BMO Capital analyst James Thalacker maintains American Electric Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEP#NASDAQ">AEP</a>) with a Outperform and raises the price target from $93 to $95.

BMO Capital Maintains Outperform on American Electric Power, Raises Price Target to $95

In the latest quarter, 9 analysts provided ratings for GE HealthCare Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEHC#NASDAQ">GEHC</a>), showcasing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated GE HealthCare Techs and provided 12-month price targets. The average target is $99.78, accompanied by a high estimate of $110.00 and a low estimate of $86.00. Marking an increase of 13.88%, the current average surpasses the previous average price target of $87.62. 
<img src="https://www.benzinga.com/files/images/story/2024/1714582853_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A comprehensive examination of how financial experts perceive GE HealthCare Techs is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anthony Petrone</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Buy</td>
<td>$105.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Anthony Petrone</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Buy</td>
<td>$110.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$100.00</td>
<td>$93.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$103.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>David Toung</td>
<td>Argus Research</td>
<td>Raises</td>
<td>Buy</td>
<td>$110.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Sezgi Oezener</td>
<td>HSBC</td>
<td>Announces</td>
<td>Buy</td>
<td>$100.00</td>
<td>-</td>
</tr>
<tr>
<td>Patrick Wood</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$86.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>Graham Doyle</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$88.00</td>
<td>$66.00</td>
</tr>
<tr>
<td>Anthony Petrone</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Buy</td>
<td>$96.00</td>
<td>$94.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to GE HealthCare Techs. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of GE HealthCare Techs compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of GE HealthCare Techs's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of GE HealthCare Techs's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/GEHC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on GE HealthCare Techs analyst ratings.</a>
<h2>All You Need to Know About GE HealthCare Techs</h2>
GE HealthCare Technologies Inc is a globally medical technology, pharmaceutical diagnostics, and digital solutions innovator company. It has four operating segments; Imaging, Ultrasound, Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). It earns a majority of its revenue from the Imaging segment.
<h3>Understanding the Numbers: GE HealthCare Techs's Finances</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: GE HealthCare Techs displayed positive results in 3 months. As of 31 December, 2023, the company achieved a solid revenue growth rate of approximately 5.43%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: GE HealthCare Techs's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 7.74%, the company may face hurdles in effective cost management.
Return on Equity (ROE): GE HealthCare Techs's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 5.65% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): GE HealthCare Techs's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 1.24%, the company may face hurdles in achieving optimal financial performance.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 1.38, caution is advised due to increased financial risk.
<h2>What Are Analyst Ratings?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

GEHC

What Analysts Are Saying About GE HealthCare Techs Stock

In the latest quarter, 11 analysts provided ratings for Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>), showcasing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $158.91, with a high estimate of $200.00 and a low estimate of $140.00. This current average has increased by 6.29% from the previous average price target of $149.50. 
<img src="https://www.benzinga.com/files/images/story/2024/1714582845_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A comprehensive examination of how financial experts perceive Neurocrine Biosciences is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mohit Bansal</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$170.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Jay Olson</td>
<td>Oppenheimer</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$200.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$150.00</td>
<td>-</td>
</tr>
<tr>
<td>Laura Chico</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$147.00</td>
<td>-</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$155.00</td>
<td>-</td>
</tr>
<tr>
<td>Anupam Rama</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$158.00</td>
<td>$148.00</td>
</tr>
<tr>
<td>Jay Olson</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$200.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Anupam Rama</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$148.00</td>
<td>$154.00</td>
</tr>
<tr>
<td>David Hoang</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$140.00</td>
<td>$141.00</td>
</tr>
<tr>
<td>Uy Ear</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$140.00</td>
<td>$116.00</td>
</tr>
<tr>
<td>Mohit Bansal</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$140.00</td>
<td>$127.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Neurocrine Biosciences. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Neurocrine Biosciences compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Neurocrine Biosciences's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Neurocrine Biosciences's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/NBIX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Neurocrine Biosciences analyst ratings.</a>
<h2>Discovering Neurocrine Biosciences: A Closer Look</h2>
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.
<h3>A Deep Dive into Neurocrine Biosciences's Financials</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Neurocrine Biosciences displayed positive results in 3 months. As of 31 December, 2023, the company achieved a solid revenue growth rate of approximately 25.05%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 28.67%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Neurocrine Biosciences's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 6.98%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Neurocrine Biosciences's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 4.84%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.19.
<h2>Analyst Ratings: Simplified</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

NBIX

Cracking The Code: Understanding Analyst Reviews For Neurocrine Biosciences

Vista Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VIST#NYSE">VIST</a>) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Vista Energy, revealing an average target of $50.0, a high estimate of $53.00, and a low estimate of $47.00. This current average has increased by 9.48% from the previous average price target of $45.67. 
<img src="https://www.benzinga.com/files/images/story/2024/1714582838_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Vista Energy. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tasso Vasconcellos</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$50.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Andres Cardona</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Neutral</td>
<td>$50.00</td>
<td>-</td>
</tr>
<tr>
<td>Alejandro Demichelis</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$53.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Tasso Vasconcellos</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$47.00</td>
<td>$40.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Vista Energy. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Vista Energy compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Vista Energy's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Vista Energy's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/VIST/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Vista Energy analyst ratings.</a>
<h2>Discovering Vista Energy: A Closer Look</h2>
Vista Energy SAB de CV is an independent oil and gas company. It is focused on shale oil and shale gas exploration at its main assets in Vaca Muerta. The company has operations in Argentina and Mexico. The company operates in a single segment- the exploration and production of Crude oil, Natural gas, and LPG. Geographically, It operates in Argentina and Mexico. it generates the majority of its revenue from Argentina.
<h3>Vista Energy's Financial Performance</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Vista Energy displayed positive results in 3 months. As of 31 March, 2024, the company achieved a solid revenue growth rate of approximately 0.05%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Energy sector.
Net Margin: Vista Energy's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 24.78%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Vista Energy's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 6.16%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Vista Energy's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 2.92%, the company may face hurdles in achieving optimal financial performance.
Debt Management: With a high debt-to-equity ratio of 0.56, Vista Energy faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>Analyst Ratings: What Are They?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

VIST

The Analyst Landscape: 4 Takes On Vista Energy

CRWD

CNBC Halftime Report Final Trades: CrowdStrike, Leidos, ONEOK

In the preceding three months, 4 analysts have released ratings for Kadant (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KAI#NYSE">KAI</a>), presenting a wide array of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $345.0, a high estimate of $360.00, and a low estimate of $300.00. Marking an increase of 1.47%, the current average surpasses the previous average price target of $340.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1714582827_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Kadant. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gary Prestopino</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$360.00</td>
<td>$360.00</td>
</tr>
<tr>
<td>Gary Prestopino</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$360.00</td>
<td>$360.00</td>
</tr>
<tr>
<td>Gary Prestopino</td>
<td>Barrington Research</td>
<td>Raises</td>
<td>Outperform</td>
<td>$360.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Gary Prestopino</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$300.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Kadant. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Kadant compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Kadant's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Kadant's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/KAI/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Kadant analyst ratings.</a>
<h2>Discovering Kadant: A Closer Look</h2>
Kadant Inc. supplies process and engineering equipment for papermaking, recycling, lumber manufacturing, and related industries. The company's three reportable segments are the Flow Control segment which consists of the fluid-handling and doctoring, cleaning, &amp; filtration product lines; the Industrial Processing segment which consists of the wood processing and stock-preparation product lines; and Material handling systems, which provides conveyor-belt equipment for industries such as mining, food processing, and packaging. The company has a geographic presence with sizable revenue from the U.S., Europe, Asia, and Canada.
<h3>Understanding the Numbers: Kadant's Finances</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Over the 3 months period, Kadant showcased positive performance, achieving a revenue growth rate of 2.83% as of 31 December, 2023. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Industrials sector.
Net Margin: Kadant's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 11.48% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Kadant's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 3.64%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 2.35%, the company showcases effective utilization of assets.
Debt Management: Kadant's debt-to-equity ratio is below the industry average. With a ratio of 0.14, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: Simplified</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Forecasting The Future: 4 Analyst Projections For Kadant

Wynn Resorts's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WYNN#NYSE">WYNN</a>) short percent of float has risen 20.16% since its last report. The company recently reported that it has 4.98 million shares sold short, which is 4.47% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.33 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Wynn Resorts Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1714582825_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Wynn Resorts has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Wynn Resorts's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Wynn Resorts's peer group average for short interest as a percentage of float is 4.72%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

WYNN

(WYNN) - Analyzing Wynn Resorts's Short Interest

Viper Energy's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VNOM#NYSE">VNOM</a>) short percent of float has risen 69.5% since its last report. The company recently reported that it has 3.48 million shares sold short, which is 5.39% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.77 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Viper Energy Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1714582819_0_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Viper Energy has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Viper Energy's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Viper Energy's peer group average for short interest as a percentage of float is 11.09%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

VNOM

Peering Into Viper Energy's Recent Short Interest

M/I Homes (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MHO#NYSE">MHO</a>) has outperformed the market over the past 15 years by 2.25% on an annualized basis producing an average annual return of 14.3%. Currently, M/I Homes has a market capitalization of $3.23 billion. 
Buying $100 In MHO: If an investor had bought $100 of MHO stock 15 years ago, it would be worth $650.82 today based on a price of $116.22 for MHO at the time of writing.
<h3>M/I Homes's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1714582818_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In M/I Homes 15 Years Ago Would Be Worth Today

Ratings for Silk Road Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SILK#NASDAQ">SILK</a>) were provided by 6 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $20.83, with a high estimate of $24.00 and a low estimate of $18.00. Surpassing the previous average price target of $15.60, the current average has increased by 33.53%.
<img src="https://www.benzinga.com/files/images/story/2024/1714582819_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of Silk Road Medical among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Robbie Marcus</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$21.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Adam Maeder</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$20.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Steve Silver</td>
<td>Argus Research</td>
<td>Announces</td>
<td>Buy</td>
<td>$24.00</td>
<td>-</td>
</tr>
<tr>
<td>Rick Wise</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$23.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Robbie Marcus</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$19.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Adam Maeder</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$18.00</td>
<td>$11.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Silk Road Medical. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Silk Road Medical compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Silk Road Medical's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Silk Road Medical's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/SILK/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Silk Road Medical analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Discovering Silk Road Medical: A Closer Look</h2>
Silk Road Medical Inc is a medical device company focused on reducing the risk of stroke and its devastating impact. The company has a new approach for the treatment of carotid artery disease called transcarotid artery revascularization, or TCAR, which it seeks to establish as the standard of care. TCAR relies on two novel concepts - minimally-invasive direct carotid access in the neck and high-rate blood flow reversal during the procedure to protect the brain - and combines novel endovascular techniques with fundamental surgical principles. TCAR using its portfolio of products has been clinically demonstrated to reduce the upfront morbidity and mortality risks commonly associated with carotid endarterectomy. The company generates all of its revenue in the United States.
<h3>Silk Road Medical: Delving into Financials</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Silk Road Medical's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2023, the company achieved a revenue growth rate of approximately 17.97%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Silk Road Medical's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -27.52%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Silk Road Medical's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -8.55%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Silk Road Medical's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -4.95%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Silk Road Medical's debt-to-equity ratio is below the industry average at 0.51, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: What Are They?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SILK

Evaluating Silk Road Medical: Insights From 6 Financial Analysts

Sunrun's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NYSE">RUN</a>) short percent of float has risen 6.34% since its last report. The company recently reported that it has 46.52 million shares sold short, which is 25.34% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.62 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Sunrun Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1714582814_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Sunrun has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Sunrun's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Sunrun's peer group average for short interest as a percentage of float is 9.57%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Is The Market Feeling About Sunrun?

BMO Capital analyst Brian Pitz maintains Amazon.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) with a Outperform and raises the price target from $215 to $220.

BMO Capital Maintains Outperform on Amazon.com, Raises Price Target to $220

RBC Capital analyst Brad Heffern maintains Center (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CSR#NYSE">CSR</a>) with a Outperform and raises the price target from $66 to $68.

RBC Capital Maintains Outperform on Center, Raises Price Target to $68

These Financial Services stocks are trading higher:-Sentage Holdings Inc (SNTG) stock is trading at $5.96, an increase of $4.19, or 233.33%, on high volume.  Sentage Holdings Inc gets a Sentiment Score of Neutral from InvestorsObserver.  -Magic Empire Global Ltd (MEGL) stock is trading at $1.03, an increase of $0.16, or 19

Financial Services Stocks Moving Up and Down Friday: SNTG, MEGL, TBLD, CARV, SDIG, WULF, IREN, BTBT

SXTC, CGA and JFBR among pre-market losers

These Financial Services stocks are trading higher:-BTCS Inc (BTCS) stock is trading at $1.92, a gain of $0.29, or 17.69%, on moderate volume.  BTCS Inc. gets a Sentiment Score of Bearish from InvestorsObserver and receives an average analyst recommendation of Strong Buy with a price target of $3.00.  -Tinybuild Inc (TBLD)

Financial Services Stocks Making Moves Tuesday: BTCS, TBLD, YRD, MEGL, SNTG, COIN, BTBT, SAI

These Financial Services stocks are trading higher:-Yiren Digital Ltd - ADR (YRD) stock is trading at $4.22, an increase of $0.56, or 12.84%, on high volume.  Yirendai Ltd ADR gets a Sentiment Score of Very Bullish from InvestorsObserver.  -SunCar Technology Group Inc (SDA) stock is trading at $8.50, an increase of $0.61,

Financial Services Stocks Moving Wednesday: YRD, SDA, ARBK, MEGL, SNTG, SOFI, TCJH, GREE

Marathon Digital, TeraWulf, Argo Blockchain in financials losers

These Financial Services stocks are trading higher:-First Foundation Inc (FFWM) stock is trading at $9.96, a rise of $0.75, or 8.09%, on average volume.  First Foundation gets a Sentiment Score of Neutral from InvestorsObserver and receives an average analyst recommendation of Strong Buy with a price target of $8.70. First

Financial Services Stocks Moving Up and Down Friday: FFWM, LNC, FHN, NMR, MEGL, WULF, SBNY, ARBK

LendingTree among financials gainers, Argo Blockchain in losers

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
The biggest pre-market stock movers are starting off the trading week as we check out all of the hottest news for Monday morning!



Moving stocks are clinical trial data, company merger plans, bankruptcy filings and more.



Let&rsquo;s get into that news down below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Yield10 Bioscience (NASDAQ:<a href="https://investorplace.com/stock-quotes/yten-stock-quote/">YTEN</a>) stock is rocketing more than 59% alongside heavy pre-market trading this morning.</li>



<li>Chenghe Acquisition (NASDAQ:<a href="https://investorplace.com/stock-quotes/chea-stock-quote/">CHEA</a>) shares are soaring over 37% following <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318029672&amp;type=PDF&amp;symbol=CHEA&amp;cdn=512bce218ae3f41dfa99fbb4fa603a82&amp;companyName=Chenghe+Acquisition+Co.&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-02-02">shareholder approval for a merger plan</a>.</li>



<li>GRIID Infrastructure (NASDAQ:<a href="https://investorplace.com/stock-quotes/grdi-stock-quote/">GRDI</a>) stock is surging more than 34% with strong early morning trading.</li>



<li>4D Molecular Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/fdmt-stock-quote/">FDMT</a>) shares are soaring over 29% with <a href="https://www.marketwatch.com/story/4d-molecular-therapeutics-shares-rise-33-after-positive-trial-data-436613d6">positive clinical trial data</a>.</li>



<li>Tritium DCFC (NASDAQ:<a href="https://investorplace.com/stock-quotes/dcfc-stock-quote/">DCFC</a>) stock is gaining 28% after being the <a href="https://www.nasdaq.com/press-release/tritium-customers-win-largest-share-of-round-1-tennessee-nevi-program-2024-02-05">top-awarded fast-charger company</a> by Tennessee&rsquo;s National Electric Vehicle Infrastructure (NEVI) Formula Program.</li>



<li>Simplify Tail Risk Strategy (NYSEARCA:<a href="https://investorplace.com/stock-quotes/cya-stock-quote/">CYA</a>) shares are rising more than 17% on Monday morning.</li>



<li>Magic Empire Global (NASDAQ:<a href="https://investorplace.com/stock-quotes/megl-stock-quote/">MEGL</a>) stock is climbing 15% as it sees heavy trading this morning.</li>



<li>BioRestorative Therapies (NASDAQ:<a href="https://investorplace.com/stock-quotes/brtx-stock-quote/">BRTX</a>) shares are jumping over 14% on Monday.</li>



<li>Alto Neuroscience (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANRO#NYSE">ANRO</a>) stock is getting a more than 14% boost following its <a href="https://www.marketwatch.com/story/alto-neuroscience-shares-soar-in-trading-debut-after-upsized-ipo-22f26d13">initial public offering</a>.</li>



<li>Catalent (NYSE:<a href="https://investorplace.com/stock-quotes/ctlt-stock-quote/">CTLT</a>) shares are up 13% after announcing a <a href="https://finance.yahoo.com/news/novo-holdings-buy-catalent-11-111946341.html">massive sale of the company</a>.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Cano Health (NYSE:<a href="https://investorplace.com/stock-quotes/cano-stock-quote/">CANO</a>) stock is crashing more than 51% alongside <a href="https://www.nasdaq.com/press-release/cano-health-enters-restructuring-support-agreement-with-a-significant-majority-of-its">a bankruptcy filing</a>.</li>



<li>NanoString Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/nstg-stock-quote/">NSTG</a>) shares are plummeting over 49% after also <a href="https://www.nasdaq.com/press-release/nanostring-takes-steps-to-restructure-its-business-and-protect-its-mission-to-map-the">filing for bankruptcy protection</a>.</li>



<li>DMK Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/dmk-stock-quote/">DMK</a>) stock is diving more than 48% <a href="https://www.nasdaq.com/press-release/dmk-pharmaceuticals-commences-restructuring-proceeding-2024-02-02">following a bankruptcy filing</a>.</li>



<li>Bit Brother (NASDAQ:<a href="https://investorplace.com/stock-quotes/bets-stock-quote/">BETS</a>) shares are tumbling over 25% after getting <a href="https://www.nasdaq.com/press-release/bit-brother-limited-receives-notice-of-delisting-from-nasdaq-2024-02-02">a delisting notice</a>.</li>



<li>Jin Medical International (NASDAQ:<a href="https://investorplace.com/stock-quotes/zjyl-stock-quote/">ZJYL</a>) stock is dropping more than 18% without any clear news this morning.</li>



<li>Oragenics (NYSEMKT:<a href="https://investorplace.com/stock-quotes/ogen-stock-quote/">OGEN</a>) shares are sliding over 13% on Monday morning.</li>



<li>Rail Vision (NASDAQ:<a href="https://investorplace.com/stock-quotes/rvsn-stock-quote/">RVSN</a>) stock is decreasing more than 12% ahead of <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318029931&amp;type=PDF&amp;symbol=RVSN&amp;cdn=4bbedcb1f3a7ff960c3216adeb5f2cde&amp;companyName=Rail+Vision+Ltd.&amp;formType=6-K%2FA&amp;formDescription=%5BAmend%5D+Report+of+foreign+issuer+%5BRules+13a-16+and+15d-16%5D&amp;dateFiled=2024-02-02">an extraordinary general shareholder meeting</a>.</li>



<li>Intelligent Bio Solutions (NASDAQ:<a href="https://investorplace.com/stock-quotes/inbs-stock-quote/">INBS</a>) shares are falling over 11% after <a href="https://www.globenewswire.com/news-release/2024/02/02/2822845/0/en/Intelligent-Bio-Solutions-Inc-Announces-Preliminary-Unaudited-Fiscal-Second-Quarter-and-Six-Month-Revenue-Results.html">releasing preliminary results for Q2</a>.</li>



<li>TruGolf (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUG#NASDAQ">TRUG</a>) stock is retreating more than 11% following its <a href="https://investorplace.com/2024/02/why-is-trugolf-trug-stock-up-35-today/">recent public debut</a>.</li>



<li>CCSC Technology (NASDAQ:<a href="https://investorplace.com/stock-quotes/cctg-stock-quote/">CCTG</a>) shares close out our pre-market stock movers down over 11% today.</li>
</ol>On the date of publication, William White&nbsp;did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/07/venture-capitalist-predicts-this-chatgpt-announcement-will-shock-the-world/?cid=MKT744191&amp;eid=MKT766413">ChatGPT IPO Could Shock the World, Make This Move Before the Announcement</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/02/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-monday-feb-5th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It&rsquo;s time to start the final day of trading this week with a breakdown of the biggest pre-market stock movers for Friday morning!



Moving stocks are heavy trading, earnings reports, clinical trial news and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Next eGo (NASDAQ:<a href="https://investorplace.com/stock-quotes/egox-stock-quote/">EGOX</a>) stock is rocketing more than 110% alongside heavy pre-market trading this morning.</li>



<li>Intelligent Living Application (NASDAQ:<a href="https://investorplace.com/stock-quotes/ilag-stock-quote/">ILAG</a>) shares are soaring over 90% with strong early morning trading on Friday.</li>



<li>TC BioPharm (NASDAQ:<a href="https://investorplace.com/stock-quotes/tcbp-stock-quote/">TCBP</a>) stock is surging more than 75% with increased trading activity this morning.</li>



<li>Top Financial (NASDAQ:<a href="https://investorplace.com/stock-quotes/top-stock-quote/">TOP</a>) shares are gaining over 75% as it also experiences heavy trading on Friday.</li>



<li>Sunworks (NASDAQ:<a href="https://investorplace.com/stock-quotes/sunw-stock-quote/">SUNW</a>) stock is rising more than 38% <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318035511&amp;type=PDF&amp;symbol=SUNW&amp;cdn=adc51c5aed5c71e14427762a8cf482ab&amp;companyName=Sunworks+Inc.&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-02-06">despite a recent bankruptcy filing</a>.</li>



<li>Cheche (NASDAQ:<a href="https://investorplace.com/stock-quotes/ccg-stock-quote/">CCG</a>) shares are increasing over 30% without any clear news today.</li>



<li>Cloudflare (NYSE:<a href="https://investorplace.com/stock-quotes/net-stock-quote/">NET</a>) stock is climbing more than 27% <a href="https://www.cnbc.com/2024/02/08/cloudflare-net-q4-earnings-report-2023.html">alongside an earnings beat</a>.</li>



<li>Magic Empire Global (NASDAQ:<a href="https://investorplace.com/stock-quotes/megl-stock-quote/">MEGL</a>) shares are jumping over 26% alongside strong early morning trading on Friday.</li>



<li>Central Garden &amp; Pet (NASDAQ:<a href="https://investorplace.com/stock-quotes/centa-stock-quote/">CENTA</a>) stock is getting a 25% boost <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318045374&amp;type=PDF&amp;symbol=CENT&amp;cdn=10c65ab88aa3d8ef8e519b4adb7f0d23&amp;companyName=Central+Garden+%26+Pet+Company&amp;formType=4&amp;formDescription=Statement+of+changes+in+beneficial+ownership+of+securities&amp;dateFiled=2024-02-08">on insider buying</a>.</li>



<li>Selina Hospitality (NASDAQ:<a href="https://investorplace.com/stock-quotes/slna-stock-quote/">SLNA</a>) shares are up more than 18% with strong trading this morning.</li>
</ol><h2>10 Top Losers</h2><ol></ol><ol><li>Synlogic (NASDAQ:<a href="https://investorplace.com/stock-quotes/sybx-stock-quote/">SYBX</a>) stock is plummeting 58% after <a href="https://finance.yahoo.com/news/synlogic-announces-decision-discontinue-synpheny-211500711.html">discontinuing a clinical trial</a>.</li>



<li>BioXcel Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/btai-stock-quote/">BTAI</a>) shares are diving over 40% after <a href="https://www.globenewswire.com/news-release/2024/02/08/2826423/0/en/BioXcel-Therapeutics-Announces-Proposed-Public-Offering.html">announcing a proposed public offering</a>.</li>



<li>Children&rsquo;s Place (NASDAQ:<a href="https://investorplace.com/stock-quotes/plce-stock-quote/">PLCE</a>) stock is tumbling more than 31% after releasing <a href="https://www.nasdaq.com/press-release/the-childrens-place-announces-preliminary-unaudited-results-for-the-fourth-quarter-0">preliminary earnings results</a>.</li>



<li>Renalytix (NASDAQ:<a href="https://investorplace.com/stock-quotes/rnlx-stock-quote/">RNLX</a>) shares are taking a close to 27% beating as it comes off a rally yesterday.</li>



<li>Syra Health (NASDAQ:<a href="https://investorplace.com/stock-quotes/syra-stock-quote/">SYRA</a>) stock is dropping over 25% following a <a href="https://investorplace.com/2024/02/why-is-syra-health-syra-stock-up-285-today/">massive rally on Thursday</a>.</li>



<li>MicroCloud Hologram (NASDAQ:<a href="https://investorplace.com/stock-quotes/holo-stock-quote/">HOLO</a>) shares are retreating more than 25% after <a href="https://investorplace.com/2024/02/microcloud-hologram-holo-stock-pops-another-10-in-speculative-rally/">rallying the last two days</a>.</li>



<li>Hitek Global (NASDAQ:<a href="https://investorplace.com/stock-quotes/hkit-stock-quote/">HKIT</a>) stock is sliding over 22% after a <a href="https://investorplace.com/2024/02/why-is-hitek-global-hkit-stock-up-518-today/">massive jump in price yesterday</a>.</li>



<li>Emcore (NASDAQ:<a href="https://investorplace.com/stock-quotes/emkr-stock-quote/">EMKR</a>) shares are falling more than 20% with its <a href="https://qz.com/emcore-fiscal-q1-earnings-snapshot-1851240456">latest earnings release</a>.</li>



<li>CCSC Technology (NASDAQ:<a href="https://investorplace.com/stock-quotes/cctg-stock-quote/">CCTG</a>) stock is slipping over 18% <a href="https://investorplace.com/2024/02/why-is-ccsc-technology-cctg-stock-up-107-today/">after a Thursday rally</a>.</li>



<li>MoneyHero (NASDAQ:<a href="https://investorplace.com/stock-quotes/mny-stock-quote/">MNY</a>) stock closes out our pre-market stock movers down more than 18% <a href="https://finance.yahoo.com/news/moneyhero-group-announces-resignation-chief-213000993.html">as its Chief Financial Officer resigns</a>.</li>
</ol>On the date of publication, William White&nbsp;did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/02/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-friday-feb-9th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Magic Empire Glb Stock (NASDAQ:MEGL), Short Interest Report

People Also Watch